Long-lasting remission of type 1 diabetes following treatment with topiramate for generalized seizures |
| |
Authors: | Alberto M. Davalli Carla Perego Franco B. Folli Emanuele Bosi |
| |
Affiliation: | (1) Department of Internal Medicine, Diabetes and Endocrinology Unit, San Raffaele Scientific Institute, and Vita-Salute San Raffaele University, Via Olgettina 60, 20132 Milan, Italy;(2) Department of Molecular Science, Universit? degli Studi di Milano, 20132 Milan, Italy;(3) Department of Medicine Diabetes Division, University of Texas Health Science Center, San Antonio, TX 78229, USA |
| |
Abstract: | We report a case of unusually long-lasting remission of type 1 diabetes (T1D). The patient, a Caucasian man, at the age of 43 years developed a ketotic diabetes, classified as type 1 based on clinical presentation and positivity for islet autoantibodies. Shortly after diabetes onset, oral topiramate was added to preexisting valproic acid for generalized seizures and maintained thereafter. Initial intensive insulin treatment was rapidly reduced to low doses (3 Units/day) maintained for a long time and then discontinued at month 55; fasting glucose and glycosylated hemoglobin were basically normalized at 58 months. An oral glucose tolerance test performed at month 53 showed an impaired fasting glucose (6.0 mmol/l) and a value slightly above the threshold for the diagnosis of diabetes at 2 h (11.2 mmol/l). We hypothesize that this unusually prolonged preservation of β-cell function might be ascribed to the concomitant therapy with topiramate, an antiepileptic agent with demonstrated efficacy as antidiabetic in type 2 diabetes (T2D). Topiramate should be further investigated as candidate agent for the preservation of β-cell function also in T1D. |
| |
Keywords: | |
本文献已被 PubMed SpringerLink 等数据库收录! |
|